Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation
Most Cited Paper
in Atrial Fibrillation Management and Outcomes
18 Months Post-Publication
Class of 2026
“Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
apixaban · aspirin · CHA2DS2-VASc score · subclinical atrial fibrillation · Device-detected atrial arrhythmias · stroke · Thromboembolism · Major bleeding · ARTESiA trial · Thromboembolism · absolute risk difference · Anticoagulation therapy · Risk stratification · patient-years · Benefit-risk assessment
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Atrial Fibrillation Management and Outcomes Papers, Class of 2026. https://pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459